All Releases
View Summary Celldex Reports Second Quarter 2017 Results
Aug 8, 2017
PDF 76.6 KB Add to Briefcase
View Summary Celldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call
Aug 2, 2017
PDF 2.1 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
Jun 16, 2017
PDF 20.7 KB Add to Briefcase
View Summary Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference
Jun 6, 2017
PDF 12.8 KB Add to Briefcase
View Summary Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting
Jun 5, 2017
PDF 64.0 KB Add to Briefcase
View Summary Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma
Jun 5, 2017
PDF 19.1 KB Add to Briefcase
View Summary Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
May 17, 2017
PDF 12.0 KB Add to Briefcase
View Summary Celldex Reports First Quarter 2017 Results
May 9, 2017
PDF 25.4 KB Add to Briefcase
View Summary Celldex Provides Corporate Update and Reports Full Year 2016 Results
Mar 14, 2017
PDF 28.2 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Appointment to Board of Directors
Mar 1, 2017
PDF 12.2 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call
Feb 13, 2017
PDF 12.6 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Appointment to Board of Directors
Dec 14, 2016
PDF 12.7 KB Add to Briefcase
View Summary Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team
Dec 5, 2016
PDF 13.2 KB Add to Briefcase
View Summary Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting
Dec 5, 2016
PDF 18.1 KB Add to Briefcase
View Summary Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Nov 29, 2016
PDF 15.2 KB Add to Briefcase
View Summary Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
Nov 14, 2016
PDF 15.6 KB Add to Briefcase
View Summary Celldex Reports Third Quarter 2016 Results
Nov 7, 2016
PDF 35.5 KB Add to Briefcase
View Summary Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals
Nov 1, 2016
PDF 21.5 KB Add to Briefcase
View Summary Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response
Oct 9, 2016
PDF 21.1 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Sep 23, 2016
PDF 9.5 KB Add to Briefcase
Showing 1-20 of 150 Page: 1 2 3 4 5 ... 8  Next 20
Showing 1-20 of 150
Page: 1 2 3 4 5 ... 8
 Next 20
Add to Briefcase = add release to Briefcase